Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity
出版年份 2016 全文链接
标题
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity
作者
关键词
-
出版物
AMERICAN JOURNAL OF EPIDEMIOLOGY
Volume 185, Issue 2, Pages 75-85
出版商
Oxford University Press (OUP)
发表日期
2016-10-26
DOI
10.1093/aje/kww178
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Breast Cancer Version 3.2014
- (2017) William J. Gradishar et al. Journal of the National Comprehensive Cancer Network
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies
- (2015) J. A. Johnson et al. JNCI-Journal of the National Cancer Institute
- RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2015) J. M. Rae et al. JNCI-Journal of the National Cancer Institute
- Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses
- (2015) Daniel L. Hertz et al. Molecular Oncology
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Tamoxifen Pharmacogenetic Studies
- (2015) J. A. Johnson et al. JNCI-Journal of the National Cancer Institute
- RE: Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2015) J. M. Rae et al. JNCI-Journal of the National Cancer Institute
- Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy
- (2014) Jessica Mwinyi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
- (2014) R. T. Chlebowski et al. Cancer Prevention Research
- CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies
- (2014) M P Goetz et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Good practices for quantitative bias analysis
- (2014) T. L. Lash et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Response
- (2014) D. A. Berry JNCI-Journal of the National Cancer Institute
- Response
- (2014) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies
- (2014) Matthew P. Goetz et al. JNCI-Journal of the National Cancer Institute
- Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
- (2014) P Saladores et al. PHARMACOGENOMICS JOURNAL
- No association found betweenCYP2D6genotype and early breast cancer events in tamoxifen-treated patients
- (2013) Andrea Markkula et al. ACTA ONCOLOGICA
- Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer
- (2013) Bent Ejlertsen et al. ACTA ONCOLOGICA
- Impact of CYP2D6 Polymorphisms on Tamoxifen Responses of Women with Breast Cancer: A Microarray-based Study in Thailand
- (2013) Chonlaphat Sukasem et al. Asian Pacific Journal of Cancer Prevention
- Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93
- (2013) Olivia Pagani et al. BREAST CANCER RESEARCH AND TREATMENT
- CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial
- (2013) V. O. Dezentjé et al. BREAST CANCER RESEARCH AND TREATMENT
- Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
- (2013) B Makubate et al. BRITISH JOURNAL OF CANCER
- The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study
- (2013) C McCowan et al. BRITISH JOURNAL OF CANCER
- Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy
- (2013) Deirdre P Cronin-Fenton et al. Future Oncology
- Concordance Between CYP2D6 Genotypes Obtained From Tumor-Derived and Germline DNA
- (2013) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
- (2013) Richard R Love et al. SpringerPlus
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
- (2012) Caitlin C. Murphy et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
- (2012) Solai Elango Damodaran et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
- (2012) M. P. Goetz et al. CLINICAL CANCER RESEARCH
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) P. D. P. Pharoah et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Y. Nakamura et al. JNCI-Journal of the National Cancer Institute
- Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) V. Stanton JNCI-Journal of the National Cancer Institute
- CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
- (2012) James M. Rae et al. JNCI-Journal of the National Cancer Institute
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
- (2012) Meredith M. Regan et al. JNCI-Journal of the National Cancer Institute
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- (2012) Christina Davies et al. LANCET
- Tamoxifen and CYP2D6: A Contradiction of Data
- (2012) D. L. Hertz et al. ONCOLOGIST
- The importance of nonpharmacogenetic factors in endocrine therapy
- (2012) Colin McCowan et al. PHARMACOGENOMICS
- The Risk of Recurrence in Breast Cancer Patients Treated with Tamoxifen: Polymorphisms of CYP2D6 and ABCB1
- (2011) L. K. Teh et al. AAPS Journal
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- (2011) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- Clinical and biomarker predictors of side effects from tamoxifen
- (2011) Wendy Lorizio et al. BREAST CANCER RESEARCH AND TREATMENT
- Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
- (2011) Joanne S. L. Lim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
- (2011) L Madlensky et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- In Vitro Assessment of the Allelic Variants of Cytochrome P450
- (2011) Masahiro Hiratsuka Drug Metabolism and Pharmacokinetics
- Is Probabilistic Bias Analysis Approximately Bayesian?
- (2011) Richard F. MacLehose et al. EPIDEMIOLOGY
- Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
- (2011) Hyung Seok Park et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
- (2011) T. L. Lash et al. JNCI-Journal of the National Cancer Institute
- Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
- (2010) Alastair M. Thompson et al. BREAST CANCER RESEARCH AND TREATMENT
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
- (2010) Dawn L. Hershman et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
- (2010) Vincent O. Dezentjé et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Effect of Polymorphisms inCYP2D6andABCC2on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
- (2010) Kazuma Kiyotani et al. JOURNAL OF CLINICAL ONCOLOGY
- Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue
- (2010) Thomas Ahern Clinical Epidemiology
- The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
- (2009) Monique J. Bijl et al. BREAST CANCER RESEARCH AND TREATMENT
- Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
- (2009) Masatsugu Okishiro et al. CANCER
- Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
- (2009) Werner Schroth JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genotype-guided tamoxifen therapy: time to pause for reflection?
- (2009) Timothy L Lash et al. LANCET ONCOLOGY
- Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
- (2009) J M Rae et al. PHARMACOGENOMICS JOURNAL
- Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment
- (2008) Y. Xu et al. ANNALS OF ONCOLOGY
- Pharmacokinetics/Genotype Associations for Major Cytochrome P450 Enzymes in Native and First- and Third-generation Japanese Populations: Comparison With Korean, Chinese, and Caucasian Populations
- (2008) SP Myrand et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Tamoxifen: Catalyst for the change to targeted therapy
- (2007) V. Craig Jordan EUROPEAN JOURNAL OF CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now